Welcome to our dedicated page for Foghorn Therapeutics SEC filings (Ticker: FHTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Foghorn Therapeutics Inc. furnished a new investor presentation dated September 2025 as an exhibit to a current report. The company plans to use this presentation in meetings and presentations with investors, offering an overview of its business and outlook in a slide format.
The investor materials are provided under a Regulation FD disclosure, which means they are being made available to the public to ensure fair access to information. The company states that the presentation is being furnished, not filed, so it is not subject to certain legal liabilities under the securities laws unless specifically incorporated into other documents.
Foghorn Therapeutics (FHTX) Q2-25 10-Q highlights:
- Revenue: Collaboration income with Eli Lilly rose 10% YoY to $7.6 m; H1-25 revenue up 13% to $13.5 m.
- Expenses: R&D fell 8% to $21.8 m and G&A fell 6% to $6.9 m, driving a 15% narrower operating loss of $21.1 m.
- Net loss: Q2 loss improved to $17.9 m (-$0.28/sh) from $23.0 m (-$0.45/sh) last year; H1 loss narrowed to $36.8 m (-$0.58/sh).
- Liquidity: Cash & cash equivalents $72.6 m; marketable securities $126.1 m; combined liquid resources $198.7 m. Management expects runway ≥12 months despite $45 m operating cash burn in H1.
- Balance sheet: Deferred revenue declined to $266.6 m as collaboration work progresses; total liabilities $302.9 m exceed assets $226.2 m, producing a $76.7 m shareholders’ deficit.
- Operations: FHD-909 (SMARCA2) transitioned to Lilly with 50/50 cost share; FHD-286 development discontinued (2024). New 10-year Watertown lease signed; Cambridge lease partially reduced, lowering future obligations by $8.5 m.
Key takeaways: Expense discipline and steady milestone revenue trimmed losses, but the pre-commercial company remains cash-burning and carries a negative equity position. Progress of the Lilly collaboration and access to additional capital remain critical catalysts.